芦可替尼对比最佳可用疗法治疗真性红细胞增多症的长期疗效与安全性:RESPONSE 3期研究5年随访
RESPONSE 3期研究5年随访显示,对于羟基脲耐药或不耐受的真性红细胞增多症患者,芦可替尼对比最佳可用疗法(BAT)虽总生存无差异,但芦可替尼组血栓栓塞事件更少、非血液学不良事件更低,且多数BAT患者交叉至芦可替尼。芦可替尼长期维持主要复合缓解的概率为74%,安全性可控。
要点
- 芦可替尼5年维持主要复合缓解概率74%,完全血液学缓解55%。
- 芦可替尼组血栓栓塞事件少于BAT组,非血液学不良事件更低。
- 贫血为芦可替尼最常见不良事件,但多为1-2级。
核心结论
- 芦可替尼是羟基脲耐药或不耐受真性红细胞增多症患者安全有效的长期治疗选择。
研究设计与样本
- 随机、开放标签、3期RESPONSE研究,纳入222例羟基脲耐药或不耐受的真性红细胞增多症患者,1:1随机分配至芦可替尼(n=110)或最佳可用疗法(n=112)。
- 芦可替尼起始剂量为10 mg每日两次口服;最佳可用疗法包括羟基脲、干扰素或聚乙二醇干扰素、哌泊溴烷、阿那格雷、获批免疫调节剂或观察。
- 主要终点为32周时复合缓解(血细胞比容控制且不需放血,同时脾体积较基线缩小≥35%),此前已报告;本次报告5年随访的缓解持久性、总生存、患者报告结局和安全性。
主要发现
- 芦可替尼组25例主要缓解者中,最终分析时6例进展;5年维持主要复合缓解的概率为74%(95% CI 51-88)。
- 5年维持完全血液学缓解的概率为55%(95% CI 32-73),维持总体临床血液学缓解的概率为67%(95% CI 54-77)。
- 非血液学不良事件长期芦可替尼治疗一般低于最佳可用疗法;血栓栓塞事件芦可替尼组低于最佳可用疗法组;芦可替尼组有2例治疗中死亡,其中1例胃腺癌被研究者评估与芦可替尼相关。
关键数值与推荐
- 5年维持主要复合缓解概率74%(95% CI 51-88)。
- 5年维持完全血液学缓解概率55%(95% CI 32-73)。
- 5年维持总体临床血液学缓解概率67%(95% CI 54-77)。
临床怎么用
- 对羟基脲耐药或不耐受的真性红细胞增多症患者,芦可替尼可作为长期治疗选择。
- 长期使用芦可替尼需监测贫血,但多数为轻中度;血栓栓塞事件较少。
- 最佳可用疗法组多数患者交叉至芦可替尼,提示芦可替尼在该人群中的可及性和耐受性。
局限性
- 开放标签设计可能影响患者报告结局和不良事件评估。
- 最佳可用疗法组大量交叉至芦可替尼,可能混淆意向性治疗比较。
- 研究由Novartis Pharmaceuticals Corporation资助。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycythaemia vera is a myeloproliferative neoplasm characterised by excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone marrow due to mutations in the Janus kinase 2 (JAK2) gene. Ruxolitinib, a JAK 1 and JAK 2 inhibitor, showed superiority over best available therapy in a phase 2 study in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea. We aimed to compare the long-term safety and efficacy of ruxolitinib with best available therapy in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea. METHODS: We report the 5-year results for a randomised, open-label, phase 3 study (RESPONSE) that enrolled patients at 109 sites across North America, South America, Europe, and the Asia-Pacific region. Patients (18 years or older) with polycythaemia vera who were resistant to or intolerant of hydroxyurea were randomly assigned 1:1 to receive either ruxolitinib or best available therapy. Patients randomly assigned to the ruxolitinib group received the drug orally at a starting dose of 10 mg twice a day. Single-agent best available therapy comprised hydroxyurea, interferon or pegylated interferon, pipobroman, anagrelide, approved immunomodulators, or observation without pharmacological treatment. The primary endpoint, composite response (patients who achieved both haematocrit control without phlebotomy and 35% or more reduction from baseline in spleen volume) at 32 weeeks was previously reported. Patients receiving best available therapy could cross over to ruxolitinib after week 32. We assessed the durability of primary composite response, complete haematological remission, overall clinicohaematological response, overall survival, patient-reported outcomes, and safety after 5-years of follow-up. This study is registered with ClinicalTrials.gov, NCT01243944. FINDINGS: We enrolled patients between Oct 27, 2010, and Feb 13, 2013, and the study concluded on Feb 9, 2018. Of 342 individuals screened for eligibility, 222 patients were randomly assigned to receive ruxolitinib (n=110, 50%) or best available therapy (n=112, 50%). The median time since polycythaemia vera diagnosis was 8·2 years (IQR 3·9-12·3) in the ruxolitinib group and 9·3 years (4·9-13·8) in the best available therapy group. 98 (88%) of 112 patients initially randomly assigned to best available therapy crossed over to receive ruxolitinib and no patient remained on best available therapy after 80 weeks of study. Among 25 primary responders in the ruxolitinib group, six had progressed at the time of final analysis. At 5 years, the probability of maintaining primary composite response was 74% (95% CI 51-88). The probability of maintaining complete haematological remission was 55% (95% CI 32-73) and the probability of maintaining overall clinicohaematological responses was 67% (54-77). In the intention-to-treat analysis not accounting for crossover, the probability of survival at 5 years was 91·9% (84·4-95·9) with ruxolitinib therapy and 91·0% (82·8-95·4) with best available therapy. Anaemia was the most common adverse event in patients receiving ruxolitinib (rates per 100 patient-years of exposure were 8·9 for ruxolitinib and 8·8 for the crossover population), though most anaemia events were mild to moderate in severity (grade 1 or 2 anaemia rates per 100 patient-years of exposure were 8·0 for ruxolitinib and 8·2 for the crossover population). Non-haematological adverse events were generally lower with long-term ruxolitinib treatment than with best available therapy. Thromboembolic events were lower in the ruxolitinib group than the best available therapy group. There were two on-treatment deaths in the ruxolitinib group. One of these deaths was due to gastric adenocarcinoma, which was assessed by the investigator as related to ruxolitinib treatment. INTERPRETATION: We showed that ruxolitinib is a safe and effective long-term treatment option for patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. Taken together, ruxolitinib treatment offers the first widely approved therapeutic alternative for this post-hydroxyurea patient population. FUNDING: Novartis Pharmaceuticals Corporation.
引用
- Kiladjian JJ, Zachee P, Hino M, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020. PMID: 31982039. doi:10.1016/S2352-3026(19)30207-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。